Investment Rating - The report maintains an "Overweight" rating for the electrophysiology-related medical consumables sector [5] Core Insights - There is a strong demand for cardiac electrophysiology technology due to the high prevalence of cardiovascular diseases in China, which ranked first among all causes of death in urban and rural residents in 2020 [2][12] - The electrophysiology technology is continuously evolving, with significant clinical advantages demonstrated through improved techniques such as three-dimensional mapping and various ablation methods [3][4] - Domestic PFA (Pulsed Field Ablation) technology presents an opportunity for local companies to catch up with foreign brands, as it is better suited to the Chinese clinical environment [4][5] Summary by Sections 1. Strong Clinical Demand for Cardiac Electrophysiology - Cardiovascular diseases have a high mortality rate, indicating a rigid clinical demand for treatment [12][13] - Cardiac electrophysiology technology is widely used for diagnosing and treating arrhythmias, with a focus on rapid arrhythmias [17][23] 2. Continuous Iteration of Electrophysiology Technology - The technology has seen significant improvements, with three-dimensional mapping providing more accurate diagnostics [3] - Various ablation techniques, including radiofrequency and cryoablation, are well-established, while PFA is rapidly developing with substantial clinical potential [3][4][55] 3. Market Growth Potential and Increasing Domestic Market Share - The domestic electrophysiology market is experiencing rapid growth, with low product penetration and unmet demand [5][50] - Historically dominated by foreign brands, the market is seeing an increase in competitiveness from domestic companies, particularly in the PFA segment [50][54] 4. PFA Technology as a Game Changer - PFA technology is advancing quickly, offering clinical advantages such as safety and efficiency, which could lead to increased adoption [55] - The approval of multiple PFA products in China is expected to accelerate market penetration and commercialization [61][63] 5. Investment Recommendations - The report suggests focusing on leading domestic companies in the electrophysiology sector, such as Huatai Medical and Microelectrophysiology, as they are likely to benefit from the growing market and technological advancements [5][54]

Core Viewpoint - Shenzhen Huitai Medical Equipment Co., Ltd. reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit driven by market expansion and product promotion [1] Financial Performance - The company achieved total operating revenue of approximately 2.584 billion yuan, representing a year-on-year increase of 25.08% [1] - The net profit attributable to shareholders was approximately 821 million yuan, reflecting a year-on-year growth of 21.91% [1] - The net profit after deducting non-recurring gains and losses was about 791 million yuan, with a year-on-year increase of 23.00% [1] Operational Highlights - The company's steady growth is attributed to continuous market development and channel deepening, which enhanced product coverage and hospital admission rates [1] - Focus on core products such as PFA (Pulsed Field Ablation) has driven market promotion and R&D iterations, leading to coordinated growth in revenue and profit [1] Asset and Equity Growth - As of the end of the reporting period, total assets were approximately 3.652 billion yuan, an increase of 22.52% compared to the beginning of the period [1] - The equity attributable to shareholders was about 3.089 billion yuan, up 22.74% from the beginning of the period [1] - The company's share capital increased to approximately 141 million shares due to the implementation of a capital reserve conversion plan [1]